Capricor expands partnership with Nippon in Europe, says Maxim

Capricor (CAPR) announced the European expansion of its partnership with Nippon Shinyaku (NPNKF), a U.S. subsidiary of NS Pharma, for exclusive commercialization and distribution of Duchenne Muscular Dystrophy treatment Deramiocel, Maxim analyst Jason McCarthy tells investors in a research note. While the deal is positive for Capricor and the expansion is further validating for Deramiocel, it may be more than that given the challenges the DMD space has faced in 2024 for exon-skipping medications on the market and gene therapy, Maxim says. The firm made no change to its Buy rating or $12 price target on Capricor shares.